Relmada Therapeutics Inc (RLMD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Relmada Therapeutics Inc (RLMD) has a cash flow conversion efficiency ratio of -0.069x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-15.07 Million) by net assets ($218.73 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Relmada Therapeutics Inc balance sheet independence to measure how much of total assets are equity-financed.
Relmada Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Relmada Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is Relmada Therapeutics Inc's earnings quality to evaluate the quality of earnings relative to operating cash generation.
Relmada Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Relmada Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhejiang Starry Pharm Co Ltd
SHG:603520
|
0.004x |
|
Ningbo Shenglong Automotive Powertrain System Co Ltd
SHG:603178
|
0.065x |
|
TELUS International
TO:TIXT
|
0.078x |
|
Skyworks Solutions Inc
SA:S1SL34
|
0.069x |
|
Qinghai Jinrui Mineral Development Co Ltd
SHG:600714
|
0.013x |
|
Gan Yuan Foods Co Ltd
SHE:002991
|
0.067x |
|
Unity Bancorp Inc
NASDAQ:UNTY
|
0.042x |
|
Allied Supreme Corp
TW:4770
|
0.048x |
Annual Cash Flow Conversion Efficiency for Relmada Therapeutics Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Relmada Therapeutics Inc from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see Relmada Therapeutics Inc (RLMD) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $86.51 Million | $-45.79 Million | -0.529x | +63.68% |
| 2024-12-31 | $35.52 Million | $-51.76 Million | -1.457x | -140.74% |
| 2023-12-31 | $85.36 Million | $-51.66 Million | -0.605x | +18.12% |
| 2022-12-31 | $140.44 Million | $-103.80 Million | -0.739x | -67.55% |
| 2021-12-31 | $208.26 Million | $-91.87 Million | -0.441x | -67.49% |
| 2020-12-31 | $105.58 Million | $-27.81 Million | -0.263x | -251866.34% |
| 2019-12-31 | $115.68 Million | $-12.09K | 0.000x | -100.01% |
| 2018-12-31 | $-5.51 Million | $-6.00 Million | 1.089x | +124.59% |
| 2017-12-31 | $1.46 Million | $-6.47 Million | -4.428x | -137.26% |
| 2016-12-31 | $7.04 Million | $-13.14 Million | -1.866x | -1.33% |
| 2015-12-31 | $8.81 Million | $-16.23 Million | -1.842x | 0.00% |
| 2014-12-31 | $8.81 Million | $-16.23 Million | -1.842x | -191.19% |
| 2014-06-30 | $-1.11 Million | $-2.24 Million | 2.020x | +18788.61% |
| 2013-12-31 | $-1.11 Million | $-11.86K | 0.011x | +101.61% |
| 2012-12-31 | $11.36K | $-7.57K | -0.666x | -- |
About Relmada Therapeutics Inc
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, whic… Read more